These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30997620)

  • 21. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
    Hui KF; Yeung PL; Chiang AK
    Oncotarget; 2016 Jan; 7(4):4454-67. PubMed ID: 26683357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.
    Hegarty SV; Togher KL; O'Leary E; Solger F; Sullivan AM; O'Keeffe GW
    Neurosci Lett; 2017 Jul; 653():12-18. PubMed ID: 28506690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
    Lohberger B; Steinecker-Frohnwieser B; Stuendl N; Kaltenegger H; Leithner A; Rinner B
    PLoS One; 2016; 11(12):e0168193. PubMed ID: 27978543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
    Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
    Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
    Sun JY; Tseng H; Xu L; Hunter Z; Ciccarelli B; Fulciniti M; Zhu B; Maghsoudi K; Yang G; Gong P; Zhou Y; Liu X; Munshi NC; Patterson CJ; Treon SP
    Leuk Lymphoma; 2011 Sep; 52(9):1777-86. PubMed ID: 21657958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRAIL treatment provokes mutations in surviving cells.
    Lovric MM; Hawkins CJ
    Oncogene; 2010 Sep; 29(36):5048-60. PubMed ID: 20639907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
    Huang Z; Peng S; Knoff J; Lee SY; Yang B; Wu TC; Hung CF
    J Biomed Sci; 2015 Jan; 22(1):7. PubMed ID: 25591912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
    Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
    Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
    Harrison SJ; Bishton M; Bates SE; Grant S; Piekarz RL; Johnstone RW; Dai Y; Lee B; Araujo ME; Prince HM
    Epigenomics; 2012 Oct; 4(5):571-89. PubMed ID: 23130838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    Chang T; Lian Z; Ma S; Liang Z; Ma X; Wen X; Wang Y; Liu R
    Prostate; 2023 Apr; 83(5):470-486. PubMed ID: 36576015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.